English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Diazepam is one of the most commonly prescribed pharmaceuticals for the treatment of alcohol withdrawal syndrome (AWS). However, diazepam sometimes is ineffective, and some patients experience dose-dependent adverse drug reactions (ADR). Previous studies have shown that diazepam metabolism involves the CYP3A4 and CYP3A5 isoenzymes, whose activity is highly variable between individuals, which may contribute to differences in clinical response. The study aimed to investigate the effects of the genetic polymorphisms  CYP3A4*22  and  CYP3A5*3  on the efficacy and safety of diazepam in patients with AWS. One hundred male AWS patients received 30 mg/day diazepam by intramuscular injections for 5 days. Genotyping for  CYP3A4*22  (rs35599367) and  CYP3A5*3  (rs776746) was performed by real-time polymerase chain reaction with allele-specific hybridization. The efficacy and safety assessments were performed using psychometric scales. Patients who carry  CT  and  TT  genotypes by polymorphic marker  C &gt; T intron 6  (rs35599367) of the  CYP3A4  gene had a higher risk for ADR and demonstrated lower safety of diazepam therapy ( p  &lt; 0.001; two-way ANOVA). These results suggest that genotyping for common CYP3A variants might have the potential to guide benzodiazepine withdrawal treatment.

CYP3A4*22 and CYP3A5*3 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome

CYP3A422 and CYP3A53 impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome